AVLN 8-K 2026-09-16

Avalyn Pharma Inc. (AVLN) 8-K dated 2026-09-16 — accession 0001193125-26-393081.

Avalyn Pharma Inc. (AVLN) common stock.

Avalyn Pharma Inc. filed a 8-K on 2026-09-16. Accession 0001193125-26-393081.

This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported AVLN revenue for 2026-06-30 was $2.7M. Net income was -$28.9M. AVLN currently screens at market cap $1.40B.

Not investment advice. The AVLN SEC hub lists recent forms. The stock page is the research view.